Welcome to our dedicated page for INVESTVIEW PFD SER B news (Ticker: INVUP), a resource for investors and traders seeking the latest updates and insights on INVESTVIEW PFD SER B stock.
Investview Inc Pfd Ser B (INVUP) is dedicated to providing state-of-the-art investment tools and proprietary systems, alongside top-notch financial education, at a highly cost-effective rate through online platforms. The company's mission is to empower individual investors to manage their financial investments and future. Investview Inc offers products such as investview.com, 7minutetrader.com, 7minuteoptions.com, and 7minutestocks.com.
Investview (OTCQB: INVU) has acquired Renu Laboratories, a manufacturer of health, beauty and wellness products. The acquisition will launch a new health and wellness business unit called myLife Wellness, operating through a B2C direct-to-consumer model. Renu Labs brings proprietary products including advanced peptide serums and operates as an FDA-registered, cGMP-compliant facility. The merger is expected to be revenue accretive by Q4 2024-Q1 2025, leveraging Investview's existing network of over 15,000 global customers and members. The company aims to expand product offerings and enhance customer retention through its iGenius global network.
Investview, Inc. (OTCQB: INVU) reported its Q2 2024 financial results, showing mixed performance. Gross revenue decreased 26.0% to $13.8 million, while net revenue fell 24.1% to $13.1 million compared to Q2 2023. However, for the six months ended June 30, 2024, net income from operations increased 45.2% to $2.3 million. The company's cash position improved, with cash and cash equivalents up 13.1% to $23.7 million from December 31, 2023.
iGenius and SAFETek, Investview's operating subsidiaries, faced challenges due to global economic headwinds and industry-specific factors like Bitcoin halving. Despite these obstacles, the company remains focused on its strategic transformation plan, exploring new business channels and potential acquisitions to drive long-term growth.
Investview (OTCQB: INVU) announced its Q1 2024 financial results, reporting significant growth across key metrics compared to Q1 2023. Gross revenue increased by 11.4% to $16.5 million, while net revenue rose 15.5% to $15.7 million. Net income from operations saw a substantial jump of 376.7% to $1.9 million. The company’s cash position improved, with cash and equivalents at $24.4 million, up 16.8% from December 2023. iGenius, a major subsidiary, achieved a 13.6% increase in net revenue to $13.0 million, driven by a 16.4% rise in subscription revenue. SAFETek's revenue also grew by 26.2% due to the rising value of Bitcoin. Despite a 25.7% increase in total liabilities to $18.7 million and a decrease in stockholders’ equity by 8.9% to $17.1 million, the repurchase of 472 million shares helped reduce outstanding shares by 20.2%. Investview's strategic moves, including the acquisition of Opencash Securities, aim at expanding its retail brokerage and financial markets presence, setting the stage for future growth.
Investview, Inc. (OTCQB: INVU) reported its financial results for the year ending December 31, 2022. The company's gross revenue decreased by 23.4% to $66.6 million, and net revenue fell 14.4% to $61.8 million. The net loss from operations decreased by 69.6% to $8.6 million, primarily due to lower non-cash impairment charges compared to the previous year. Cash and equivalents declined to $20.5 million, while outstanding debt dropped to $10.5 million. The company's SAFETek operations faced challenges with net revenue down 48.1%, while iGenius experienced a modest 1.4% revenue increase.
FAQ
What is the core mission of Investview Inc Pfd Ser B?
What are the main products offered by Investview Inc Pfd Ser B?
How does Investview Inc Pfd Ser B support individual investors?
Who can benefit from Investview Inc Pfd Ser B's services?